Sol-Gel Q2 FY26 net loss widens to $3.7 million; revenue drops 96.58% to $591,000
SLGL•Expenses and liquidity
R&D expense fell to $3.7 million from $4.6 million; G&A declined to $1.0 million from $1.4 million.
Cash, cash equivalents, deposits, and marketable securities totaled $49.3 million as of June 30, 2026; runway is seen into Q1 2028.
Q2 revenue and loss widen
Sol-Gel reported Q2 2026 revenue of $0.6 million, down from $17.3 million a year earlier.
Net loss widened to $3.7 million, swinging from net income of $11.6 million; diluted loss per share was $1.13.
Phase 3 SGT-610 trial update
Phase 3 SGT-610 Gorlin trial: 9% dropout rate; last patient last visit expected September 2026, with top-line results due late November 2026.
